Roger Song, an analyst from Jefferies, maintained the Buy rating on TG Therapeutics (TGTX – Research Report). The associated price target remains the same with $46.00.
Roger Song has given his Buy rating due to a combination of factors that highlight TG Therapeutics’ strategic positioning and growth potential in the market. The company is emphasizing its differentiated anti-CD20 profile, which sets it apart from competitors like Ocrevus. This distinction is expected to help TG Therapeutics expand its market reach as it continues to develop its subcutaneous formulation.
Additionally, the company is targeting a leading position in the intravenous anti-CD20 market for multiple sclerosis, with a focus on increasing its market share from the current 25% to over 50%. The company’s proprietary technology for its subcutaneous product, Briumvi, which features a smaller volume autoinjector, is another key advantage. Furthermore, TG Therapeutics is actively engaging with healthcare providers to promote Briumvi prescriptions, aiming to capitalize on existing prescribing habits. These strategic initiatives, coupled with the company’s robust pipeline and potential partnerships, underpin Roger Song’s positive outlook and Buy rating for TG Therapeutics.
In another report released on March 12, TD Cowen also maintained a Buy rating on the stock with a $50.00 price target.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TGTX in relation to earlier this year.
Questions or Comments about the article? Write to editor@tipranks.com